Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Metsera, Inc. ( (MTSR) ) has issued an update.
On September 21, 2025, Metsera, Inc. entered into a merger agreement with Pfizer Inc., under which Pfizer will acquire Metsera for $47.50 per share in cash, valuing the transaction at approximately $4.9 billion. The merger, expected to close in the fourth quarter of 2025, will make Metsera a wholly owned subsidiary of Pfizer, enhancing Pfizer’s portfolio with Metsera’s promising therapeutic candidates for obesity and cardiometabolic diseases. The acquisition includes contingent value rights for additional payments tied to specific clinical and regulatory milestones. The merger is subject to customary closing conditions, including regulatory approvals and Metsera stockholder approval.
The most recent analyst rating on (MTSR) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Metsera is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases. The company is advancing a portfolio of oral and injectable incretin, non-incretin, and combination therapies with potential best-in-class profiles to address evolving weight loss treatment needs.
Average Trading Volume: 1,436,258
Technical Sentiment Signal: Hold
Current Market Cap: $3.5B
For a thorough assessment of MTSR stock, go to TipRanks’ Stock Analysis page.